| |
No. of total patients ( N =303)
|
No. of events ( N =87)
|
Adjusted HRa (95% CI)
|
P
|
|---|
|
Lipocalin-2
|
continuous
| | |
1.06 (1.02-1.09)
|
0.001
|
|
(ng/ml)
|
t1
|
100
|
22
|
1.00 (reference)
| |
| |
t2
|
102
|
35
|
1.96 (1.12-3.43)
|
0.018
|
| |
t3
|
101
|
30
|
1.93 (1.07-3.47)
|
0.028
|
| |
P
trend
| | |
1.36 (1.03-1.79)
|
0.029
|
|
MMP-9
|
continuous
| | |
1.02 (0.99-1.06)
|
0.136
|
|
(ng/ml)
|
t1
|
100
|
22
|
1.00 (reference)
| |
| |
t2
|
102
|
34
|
1.95 (1.12-3.39)
|
0.018
|
| |
t3
|
101
|
31
|
1.70 (0.97-2.99)
|
0.065
|
| |
P
trend
| | |
1.28 (0.99-1.67)
|
0.063
|
|
Combined scoreb
|
low
|
101
|
24
|
1.00 (reference)
| |
| |
medium
|
100
|
28
|
1.55 (0.88-2.74)
|
0.130
|
| |
high
|
102
|
35
|
2.22 (1.29-3.84)
|
0.004
|
| |
P
trend
| | |
1.49 (1.14-1.95)
|
0.004
|
-
a Adjusted for BMI (< 25 and ≥25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).
-
b The subjects were categorized into three groups based on the tertiles of combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score groups.
